TUSC2 Immunotherapy Combined With PD-1 Blockade for Tumor Regression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer therapies targeting tumor suppressor genes, such as TUSC2, lack efficacy enhancement strategies, particularly when combined with immune checkpoint inhibitors.
Innovation Solution
Administering TUSC2 therapy in conjunction with immune checkpoint inhibitors, such as anti-PD1 antibodies, to enhance anti-tumor efficacy by modulating immune cell populations and restoring normal cellular growth controls.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tumor suppressor therapy (TUSC2) is administered alone, then tumor suppressor function is restored, but anti-tumor efficacy is insufficient
Solution Approach 1:
The patent combines tumor suppressor therapy (TUSC2) with immune checkpoint inhibitors (anti-PD1, anti-CTLA4) to create a synergistic combination therapy. This merging of two different therapeutic mechanisms restores tumor suppressor function while simultaneously blocking immune checkpoint pathways, resulting in enhanced anti-tumor efficacy and improved tumor regression compared to monotherapy approaches.
2Productivity
If immune checkpoint inhibitors are administered alone, then immune response is activated, but tumor-specific immunity is insufficient
Solution Approach 1:
The patent employs TUSC2 therapy to restore tumor suppressor function specifically in cancer cells, creating a localized effect that makes tumor cells more recognizable to the immune system. When combined with immune checkpoint inhibitors that activate systemic immune response, this local restoration of tumor suppressor function enhances tumor-specific immunity by providing distinct immunogenic signals from the tumor cells themselves.
3Reliability
If combination therapy is administered, then anti-tumor efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent employs TUSC2 therapy to preliminarily restore tumor suppressor function in cancer cells before or concurrent with immune checkpoint inhibitor administration. This preliminary restoration of tumor suppressor function primes the tumor cells for enhanced immune recognition, allowing the subsequent immune checkpoint blockade to act more effectively with potentially reduced dosing requirements and simplified treatment monitoring.
Data Source
AI summary
A method of treating a subject having a cancer comprising administering a tumor suppressor therapy, such as a TUSC2 therapy, in conjunction with an immune checkpoint inhibitor. Kits and reagents for use in cancer therapy are also provided.